31 valent pneumococcal conjugate vaccine

BIOLOGICAL2 trials

Sponsors

Vaxcyte, Inc.

Conditions

Pneumococcal Vaccines

Phase 1

Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

CompletedNCT06151288

Vaxcyte, Inc.Pneumococcal Vaccines

Start: 2023-11-08End: 2024-07-17Updated: 2025-07-28

Phase 3

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

Active, not recruitingNCT07284654

Vaxcyte, Inc.Pneumococcal Vaccines

Start: 2025-12-01End: 2027-01-01Updated: 2026-03-31